Verastem’s (VSTM) “Buy” Rating Reaffirmed at Cann
Verastem, Inc. (NASDAQ:VSTM)‘s stock had its “buy” rating reaffirmed by stock analysts at Cann in a research note issued to investors on Wednesday.
Other research analysts have also recently issued research reports about the stock. Cantor Fitzgerald restated a “hold” rating and set a $2.00 price target on shares of Verastem in a research note on Thursday, May 11th. Zacks Investment Research upgraded shares of Verastem from a “sell” rating to a “hold” rating in a research note on Thursday, May 25th. HC Wainwright set a $7.00 price target on shares of Verastem and gave the stock a “buy” rating in a research note on Thursday, August 10th. Jefferies Group LLC restated a “hold” rating and set a $1.50 price target on shares of Verastem in a research note on Wednesday, June 28th. Finally, Oppenheimer Holdings, Inc. set a $6.00 price target on shares of Verastem and gave the stock a “buy” rating in a research note on Sunday, June 4th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $4.61.
Verastem (NASDAQ:VSTM) traded up 2.53% during trading on Wednesday, hitting $3.24. The stock had a trading volume of 436,207 shares. The stock has a 50-day moving average price of $3.35 and a 200-day moving average price of $2.19. The company’s market cap is $119.85 million. Verastem has a 52 week low of $1.05 and a 52 week high of $4.67.
Verastem (NASDAQ:VSTM) last announced its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.36) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by $0.02. Equities analysts predict that Verastem will post ($1.38) EPS for the current year.
TRADEMARK VIOLATION NOTICE: This article was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark laws. The legal version of this article can be accessed at https://www.americanbankingnews.com/2017/08/16/verastems-vstm-buy-rating-reaffirmed-at-cann.html.
Several hedge funds have recently bought and sold shares of the company. Alpine Woods Capital Investors LLC purchased a new stake in Verastem during the second quarter valued at $109,000. TFS Capital LLC purchased a new stake in Verastem during the first quarter valued at $113,000. Northern Trust Corp raised its stake in Verastem by 40.3% in the second quarter. Northern Trust Corp now owns 73,750 shares of the biopharmaceutical company’s stock valued at $160,000 after buying an additional 21,178 shares during the last quarter. OxFORD Asset Management LLP purchased a new stake in Verastem during the second quarter valued at $234,000. Finally, Dimensional Fund Advisors LP raised its stake in Verastem by 697.6% in the second quarter. Dimensional Fund Advisors LP now owns 289,828 shares of the biopharmaceutical company’s stock valued at $632,000 after buying an additional 253,492 shares during the last quarter. 22.35% of the stock is owned by institutional investors.
Verastem Company Profile
Verastem, Inc is a biopharmaceutical company. The Company is focused on discovering and developing drugs to improve outcomes for patients with cancer. The Company operates in the segment of developing drugs for the treatment of cancer. The Company’s advanced product candidates are VS 6063, VS 4718 and VS 5584.
Receive News & Ratings for Verastem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verastem Inc. and related companies with MarketBeat.com's FREE daily email newsletter.